Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Cancer Survivors Found to Be at Greater Risk of Frailty-Related Bone Fractures

November 18, 2022
By Nicholas Wrigley
Article

Factors such as chemotherapy treatment and a cancer diagnosis within the past 5 years were associated with a greater risk of frailty-related bone fractures among older cancer survivors, according to findings from a recent cohort study.

Cancer survivors have a significantly higher risk of frailty-related bone fractures for several years after diagnosis vs those without a history of cancer, according to findings from a recent study published in JAMA Oncology.

Older adults with a history of cancer were found to have a 57% greater risk of fractures in the first year after diagnosis (HR 1.57; 95% CI, 1.38-1.79) vs those without. The risk was especially elevated for those diagnosed with distant metastases 1 to 4 years prior to the study (HR 2.12; 95% CI, 1.75-2.58). This disparity in risk derived largely from vertebral (HR 2.46; 95% CI, 1.93-3.13) and pelvic (HR, 2.46; 95% CI 1.84-3.29) fractures. The risk of radial fracture meanwhile did not substantially vary based on history of cancer (HR 1.09; 95% CI, 0.64-1.87).

“Cancer survivors are at higher risk of bone fractures likely because of higher rates of osteoporosis coupled with low muscle mass, poor balance, and unexpected changes in gait,” the investigators wrote. “One novel finding in this study was the difference in risk by fracture site….[It] is important to understand the differences in risk by fracture site because each fracture type is associated with certain health care costs and risks of subsequent morbidity and mortality. Pelvic fractures, in particular, are highly associated with further health issues, including mortality, and account for nearly 77% of all costs incurred from incident fractures.”

Other relevant risk factors included treatment modality, lifestyle, and sex. Survivors of cancer who received chemotherapy were 31% more likely to have a fracture vs those who didn’t receive chemotherapy (HR 1.31; 95% CI, 1.09-1.57) in the first 4 years after diagnosis and 22% more likely 5 or more years beyond diagnosis (HR 1.22; 95% CI, 0.99-1.51). Additionally, survivors who were current smokers at the time of the study were more than twice as likely to have fractures (HR 2.27; 95% CI, 1.55-3.33) as those who never smoked. The risk of fracture was lower among physically active survivors 5 or more years after diagnosis (HR 0.76; 95% CI, 0.54-1.07), but this correlation was not statistically significant. Higher BMI (≥25) was also associated with lower risk of fracture for those with (HR 0.72; 95% CI, 0.62-0.85) and without (HR 0.78; 95% CI, 0.75-0.81) a history of cancer. Men were generally less likely to experience fractures than women, including in those without a history of cancer (HR 0.51; 95% CI, 0.48-0.54), in survivors 1 to 4 years after diagnosis (HR 0.53; 95% CI, 0.41-0.69), and in survivors 5 or more years beyond (HR, 0.74; 95% CI, 0.54-1.01), though the latter correlation was not statistically significant.

This longitudinal cohort study examined 92,413 eligible participants out of 116,355 adults who completed the 1999 Cancer Prevention Study II Nutrition Cohort survey and were linked with Medicare claims from 1999 to 2017. The vast majority of this study population were White (97.9%) and older than 60 years (95.8%) at the time of the survey. The median age was 69.4 years, and most participants were women (56%). Most either met (24.1%) or significantly exceeded (32.3%) the guidelines for moderate to vigorous physical activity, and most (54.2%) had a BMI of 25 or greater. Current smokers comprised 4.7% of the population, with former smokers comprising a further 48.6%.

Incident fractures affected 12,943 participants in total. The primary analysis only included first fractures because roughly 4% (n = 3793) of participants experienced more than one; further exploratory analyses assessed the risks related to multiple fractures.

“Future studies are needed that explore the associations of [moderate- to vigorous-intensity physical activity], strength training, smoking, alcohol use, or diet quality across the life course, both before and after diagnosis, with fracture risk in [survivors of cancer],” the investigators concluded, writing nonetheless that “[these] survivors, especially those who received chemotherapy or received a cancer diagnosis more recently (<5 years), may benefit from clinical guidance on frailty-related fracture prevention.”

Reference

Rees-Punia E, Newton CC, Parsons HM, et al. Fracture risk among older cancer survivors compared with older adults without a history of cancer. JAMA Oncol. Published online November 3, 2022. doi:10.1001/jamaoncol.2022.5153

Recent Videos
Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.
Hydration and a healthy, well-balanced diet may mitigate fatigue among patients undergoing treatment for cancer.
Bland foods, such as crackers and chicken noodle soup, as well as fluids with electrolytes, may help stave off treatment-related nausea.
According to Denise B. Reynolds, RD, patients eating well should not be experiencing nutritional deficiencies during cancer treatment.
Related Content
Advertisement

Black patients experienced lower survival rates across cancer types and several categories of urbanicity, particularly in breast and colorectal cancers.

Five-Year Cancer Survival Rates Lower Among Rural Cancer Populations

Roman Fabbricatore
September 25th 2025
Article

Black patients experienced lower survival rates across cancer types and several categories of urbanicity, particularly in breast and colorectal cancers.


Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.


Greater regulatory and policy clarity may better optimize clinician use of artificial intelligence in treating patients with cancer.

Advancing AI in Oncology: Critical Considerations for Clinical Practice

Roman Fabbricatore
September 19th 2025
Article

Greater regulatory and policy clarity may better optimize clinician use of artificial intelligence in treating patients with cancer.


How to Discuss Death: A Conversation of Mortality in Cancer Care

How to Discuss Death: A Conversation of Mortality in Cancer Care

Daniel C. McFarland, DO;William Breitbart, MD
September 22nd 2025
Podcast

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.


Clinical benefit with the investigational agent was reported among 48% of patients with solid tumors at or above the therapeutic dose threshold.

LP-184 Shows Favorable Safety, Pharmacokinetics in Advanced Solid Tumors

Roman Fabbricatore
September 17th 2025
Article

Clinical benefit with the investigational agent was reported among 48% of patients with solid tumors at or above the therapeutic dose threshold.


Rezatapopt Yields Responses Across TP53 Y220C-Mutated Solid Tumor Types

Rezatapopt Yields Responses Across TP53 Y220C-Mutated Solid Tumor Types

Tim Cortese
September 10th 2025
Article

Rezatapopt achieved an ORR of 33% in all patients, and an ORR of 43% in patients with ovarian cancer, with 1 confirmed complete response.

Related Content
Advertisement

Black patients experienced lower survival rates across cancer types and several categories of urbanicity, particularly in breast and colorectal cancers.

Five-Year Cancer Survival Rates Lower Among Rural Cancer Populations

Roman Fabbricatore
September 25th 2025
Article

Black patients experienced lower survival rates across cancer types and several categories of urbanicity, particularly in breast and colorectal cancers.


Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.


Greater regulatory and policy clarity may better optimize clinician use of artificial intelligence in treating patients with cancer.

Advancing AI in Oncology: Critical Considerations for Clinical Practice

Roman Fabbricatore
September 19th 2025
Article

Greater regulatory and policy clarity may better optimize clinician use of artificial intelligence in treating patients with cancer.


How to Discuss Death: A Conversation of Mortality in Cancer Care

How to Discuss Death: A Conversation of Mortality in Cancer Care

Daniel C. McFarland, DO;William Breitbart, MD
September 22nd 2025
Podcast

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.


Clinical benefit with the investigational agent was reported among 48% of patients with solid tumors at or above the therapeutic dose threshold.

LP-184 Shows Favorable Safety, Pharmacokinetics in Advanced Solid Tumors

Roman Fabbricatore
September 17th 2025
Article

Clinical benefit with the investigational agent was reported among 48% of patients with solid tumors at or above the therapeutic dose threshold.


Rezatapopt Yields Responses Across TP53 Y220C-Mutated Solid Tumor Types

Rezatapopt Yields Responses Across TP53 Y220C-Mutated Solid Tumor Types

Tim Cortese
September 10th 2025
Article

Rezatapopt achieved an ORR of 33% in all patients, and an ORR of 43% in patients with ovarian cancer, with 1 confirmed complete response.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.